Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China’s National Medical Products Administration (NMPA) has approved the clinical trial application for BL-M11D1 for Injection, a CD33‑targeting antibody‑drug conjugate (ADC), for relapsed or refractory myelodysplastic syndromes (r/r MDS). The approval expands the ADC’s development beyond ongoing acute myeloid leukemia (AML) trials in China and the US, leveraging the same platform technology as the company’s approved iza‑bren (Izalutinab brengonatcan).
Relapsed or refractory myelodysplastic syndromes (r/r MDS)
Ongoing Trials
Phase Ib (China) + Phase I (US) for r/r AML
ADC Platform Synergy
Asset
Target
Indication
Status
Iza‑bren
EGFR×HER3
Multiple cancers
Approved (China); Phase III (TNBC)
BL-M11D1
CD33
r/r AML, r/r MDS (new)
Phase I/ Ib ongoing; MDS trial approved
Strategic Implications
CD33 Target Validation: CD33 is highly expressed on myeloid malignancies (AML blasts, MDS dysplastic cells); gemtuzumab ozogamicin (Pfizer) established proof‑of‑concept, but BL-M11D1’s novel linker‑payload may offer improved efficacy and safety.
Platform Leverage: Using the same ADC platform as iza‑bren—which achieved positive Phase III data—de‑risks BL-M11D1 development through validated manufacturing, linker stability, and payload potency.
MDS Market Opportunity:Relapsed/refractory MDS has limited effective therapies beyond hypomethylating agents (azacitidine, decitabine) and transfusions; ADCs represent novel mechanism for high‑risk disease progression.
Dual‑Market Strategy:Simultaneous China + US development (AML) with MDS expansion in China maximizes regulatory optionality and global partnership attractiveness.
Market Context
Factor
Impact
MDS Market Size
~ $2 billion globally; high‑risk r/r MDS represents underserved segment with 6‑12 month median survival
CD33 ADC Competition
Gemtuzumab ozogamicin approved for AML; no approved CD33 ADCs for MDS; BL-M11D1 positioned for first‑in‑class MDS indication
Biokin ADC Leadership
Iza‑bren success establishes Biokin as China’s leading ADC developer; BL-M11D1 validates platform reproducibility across different targets
Myeloid Malignancy Pipeline
CD33 + EGFR×HER3 assets create hematology‑oncology franchise; potential for combination strategies and sequential therapy approaches
Forward‑Looking Statements This brief contains forward‑looking statements regarding MDS Phase I enrollment, AML clinical data readouts, and CD33 target validation in myelodysplastic disease. Actual results may differ due to risks including myelosuppression toxicity, competitive CD33‑directed therapies, and manufacturing scale‑up for dual‑indication supply.-Fineline Info & Tech
